Endocrine Tumor Board: Ten Years' Experience of a Multidisciplinary Clinical Working Conference.
Journal
The Permanente journal
ISSN: 1552-5775
Titre abrégé: Perm J
Pays: United States
ID NLM: 9800474
Informations de publication
Date de publication:
2020
2020
Historique:
entrez:
15
7
2020
pubmed:
15
7
2020
medline:
23
6
2021
Statut:
ppublish
Résumé
Advances in specialized medical areas and updated clinical guidelines show a need for a focused approach for patients with specific disorders. To describe a multidisciplinary tumor board for patients with endocrine tumors. We established an endocrine tumor board at a large health maintenance organization and studied cases presented between September 2007 and August 2017. To resolve diagnostic and/or therapeutic questions, a multidisciplinary team of specialists discussed patients' clinical presentations. Cases were broken down into diagnostic categories, demographic characteristics (age, sex), and need for repeated presentations to the board. We included 608 patients: 401 female (66%) and 207 male (34%). Ages ranged from teens to more than 90 years, with the peak decade 50 to 59 years (26%). Although most patients needed only 1 presentation to the board, 151 (25%) required representation, for a total of 853 presentations. The diagnoses reflected the workup status with tumor identification and localization at the initial case presentation. Diagnoses included thyroid cancer (234 patients, 38.4%), adrenal mass (165 patients, 27.1%), primary hyperparathyroidism (120 patients, 19.7%), thyroid nodule (95 patients, 15.6%), and extrathyroidal mass (23 patients, 3.8%). Other diagnoses composed the remaining 14.6%. Tumor board attendees overwhelmingly supported the meetings' benefits, with all clinicians reporting frequently changing patient management because of the meetings. Patients with endocrine tumors may benefit from a specialized approach to care. A multidisciplinary tumor board can focus discussions efficiently, provide a forum to advance care, apply endocrine-related clinical guidelines, and lead to recommendations that clinicians often employed.
Identifiants
pubmed: 32663125
pii: 19.140
doi: 10.7812/TPP/19.140
pmc: PMC7358002
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
J Clin Endocrinol Metab. 2014 Nov;99(11):3933-51
pubmed: 25356808
J Clin Endocrinol Metab. 2015 Aug;100(8):2807-31
pubmed: 26222757
J Clin Endocrinol Metab. 2016 May;101(5):1889-916
pubmed: 26934393
World J Surg. 2011 Sep;35(9):1970-6
pubmed: 21604049
J Clin Endocrinol Metab. 2014 Oct;99(10):3561-9
pubmed: 25162665
J Clin Endocrinol Metab. 2014 Jun;99(6):1915-42
pubmed: 24893135
Thyroid. 2017 Nov;27(11):1341-1346
pubmed: 29091573
J Clin Endocrinol Metab. 2011 Apr;96(4):894-904
pubmed: 21474686
Proc (Bayl Univ Med Cent). 2006 Apr;19(2):130-1
pubmed: 16609739
J Cancer Educ. 2002 Summer;17(2):97-100
pubmed: 12092861
Thyroid. 2016 Jan;26(1):1-133
pubmed: 26462967